Cite
HARVARD Citation
Swain, S. et al. (2023). Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. European journal of cancer. pp. 70-81. [Online].